{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:13:01Z","timestamp":1788873181732,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05502-2","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:37:53Z","timestamp":1782290273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline vitamin D levels and progression-free survival in patients with HR+\/HER2\u2212metastatic breast cancer treated with ribociclib: a retrospective single-center analysis"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-2633","authenticated-orcid":false,"given":"Selahattin","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng\u00fc","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"G\u00fclc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u0131l\u015fa M\u0131zrak","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr Berna","family":"\u00d6ks\u00fczo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"3","key":"5502_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"6797","key":"5502_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"26","key":"5502_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMx180043","volume":"379","author":"G Hortobagyi","year":"2018","unstructured":"Hortobagyi G. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2018;379(26):2582\u20132582.","journal-title":"N Engl J Med"},{"issue":"24","key":"5502_CR4","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5502_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"5502_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1152\/physrev.00014.2015","volume":"96","author":"S Christakos","year":"2016","unstructured":"Christakos S, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365\u2013408.","journal-title":"Physiol Rev"},{"issue":"5","key":"5502_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc3691","volume":"14","author":"D Feldman","year":"2014","unstructured":"Feldman D, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342\u201357.","journal-title":"Nat Rev Cancer"},{"key":"5502_CR8","doi-asserted-by":"crossref","unstructured":"Swarnkar M et al. Association between vitamin D deficiency and tumor characteristics in breast cancer patients. Cureus. 2024. 16(6):e62296.","DOI":"10.7759\/cureus.62296"},{"issue":"3","key":"5502_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2016.4188","volume":"3","author":"S Yao","year":"2017","unstructured":"Yao S, et al. Higher serum levels of vitamin D at diagnosis are associated with better survival in a prospective cohort of 1,666 women with breast cancer: A case-cohort analysis in the Pathways Study. JAMA Oncol. 2017;3(3):351.","journal-title":"JAMA Oncol"},{"issue":"7","key":"5502_CR10","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/nu5072502","volume":"5","author":"B Prietl","year":"2013","unstructured":"Prietl B, et al. Vitamin D and immune function. Nutrients. 2013;5(7):2502\u201321.","journal-title":"Nutrients"},{"issue":"6","key":"5502_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2310\/JIM.0b013e31821b8755","volume":"59","author":"C Aranow","year":"2011","unstructured":"Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881\u20136.","journal-title":"J Investig Med"},{"issue":"18","key":"5502_CR12","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.3390\/cancers16183211","volume":"16","author":"S Dallavalasa","year":"2024","unstructured":"Dallavalasa S, et al. Vitamin D in cancer prevention and treatment: A review of epidemiological, preclinical, and cellular studies. Cancers. 2024;16(18):3211.","journal-title":"Cancers"},{"issue":"24","key":"5502_CR13","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.3390\/cancers16244206","volume":"16","author":"A Ottaiano","year":"2024","unstructured":"Ottaiano A, et al. Impact of Vitamin D Levels on Progression-Free Survival and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers. 2024;16(24):4206.","journal-title":"Cancers"},{"issue":"7","key":"5502_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/carcin\/bgs187","volume":"33","author":"S Hatse","year":"2012","unstructured":"Hatse S, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012;33(7):1319\u201326.","journal-title":"Carcinogenesis"},{"issue":"4","key":"5502_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/er.2018-00126","volume":"40","author":"R Bouillon","year":"2019","unstructured":"Bouillon R, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2019;40(4):1109\u201351.","journal-title":"Endocr Rev"},{"issue":"9","key":"5502_CR16","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.4049\/jimmunol.0803217","volume":"183","author":"LE Jeffery","year":"2009","unstructured":"Jeffery LE, et al. 1, 25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458\u201367.","journal-title":"J Immunol"},{"issue":"11","key":"5502_CR17","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/jbmr.3884","volume":"34","author":"R Bouillon","year":"2019","unstructured":"Bouillon R, Bikle D. Vitamin D metabolism revised: fall of dogmas. J Bone Miner Res. 2019;34(11):1985\u201392.","journal-title":"J Bone Miner Res"},{"issue":"7668","key":"5502_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"key":"5502_CR19","doi-asserted-by":"publisher","first-page":"886238","DOI":"10.3389\/fendo.2022.886238","volume":"13","author":"J Vanhevel","year":"2022","unstructured":"Vanhevel J, et al. The combination of the CDK4\/6 inhibitor, palbociclib, with the vitamin D3 analog, inecalcitol, has potent in vitro and in vivo anticancer effects in hormone-sensitive breast cancer, but has a more limited effect in triple-negative breast cancer. Front Endocrinol. 2022;13:886238.","journal-title":"Front Endocrinol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05502-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05502-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:02:32Z","timestamp":1788872552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05502-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5502"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05502-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Ethics Committee of Ankara Etlik City Training and Research Hospital (Approval No AE\u015eH BADEK2 2025 225). The requirement for written informed consent was waived due to the retrospective design. All procedures were conducted in accordance with the Declaration of Helsinki. The requirement for written informed consent to participate was waived owing to the retrospective design by the Clinical Research Ethics Committee of Ankara Etlik City Training and Research Hospital (Ankara, T\u00fcrkiye).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as no identifiable data or images are present within the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1304"}}